Alvotech (ALVO) - News Archive

Reykjavik, Iceland and London, UK In a notable stride for the biosimilars industry, Alvotech, a global leader in the development and manufacture of biosimilar medicines, and its partner Advanz Pharma have successfully s...

New York-based Kirby McInerney LLP has announced an investigation into Alvotech, a biotechnology firm listed on NASDAQ under the ticker ALVO, for potential securities fraud. The law firm is scrutinizing whether Alvotech...

Alvotech (NASDAQ: ALVO), a leading global biotech company focused on developing and manufacturing biosimilar medicines, has recently made significant announcements concerning its financial performance and strategic enga...

In the dynamic realm of biopharmaceuticals, regulatory challenges and breakthroughs can dramatically reshape the landscape for companies involved in drug development. Alvotech, a global biotech company specializing in t...

The Rise of Biosimilars: Alvotech s Bold Stride into the European MarketIn an exciting development for the world of medicine, Alvotech, a prominent global biotech firm specializing in the development of biosimilars, has...

The biotechnology landscape is continuously evolving, driven by scientific advancements and the growing demand for affordable therapies. A notable development in this sector is the recent private placement completed by...

Alvotech, a dedicated biotechnology company specializing in the development of high-quality biosimilars, has announced its intention to engage in a private placement of approximately 7.5 million Swedish Depository Recei...

As preparations ramp up for Alvotech s Annual General Meeting on June 25, 2025, at the esteemed premises of Arendt & Medernach in Luxembourg, the company stands poised at a critical juncture in its development. This mee...

Alvotech (NASDAQ: ALVO), a prominent global biotech company dedicated to the development and manufacture of biosimilar medicines, is gearing up for its participation in the upcoming BofA Securities Healthcare Conference...

Alvotech Bolsters Global Biosimilar Leadership through Acquisition of Xbrane s R&D Operations in Sweden In a significant development for the global biosimilars market, Alvotech (NASDAQ: ALVO), a leading biotech firm ren...

Breaking News: Alvotech Expands Global Footprint with Acquisition of Xbrane Biopharma s R&D Operations and Biosimilar CandidateStockholm, Sweden — In a decisive move that enhances its position in the burgeoning biosimil...

In an impressive leap for the world s burgeoning biosimilars market, Alvotech, a prominent global biotech firm headquartered in Reykjavik, Iceland, and Dr. Reddy’s Laboratories, based in Hyderabad, India, announced on M...

In a significant advancement for the biosimilar market, Teva Pharmaceuticals and Alvotech have announced the availability of SELARSDI (ustekinumab-aekn) injection in the U.S. This new product is a biosimilar to Stelara...

Alvotech s Strategic Advancements and Financial Performance in 2024: Pioneering the Future of Biosimilars In the rapidly advancing field of biotechnology, biosimilar medicines offer transformative potential to enhance p...

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi REYKJAVIK, Iceland and LONDON, Nov. 4, 2024 In a significant advancement for the biosimila...

European Medicines Agency Accepts Alvotech s Marketing Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva Alvotech, a global biotech entity listed on NASDAQ under the ticker ALVO, has announced a significa...

Alvotech (NASDAQ: ALVO), a prominent global biotechnology firm specializing in the development and manufacturing of biosimilar medicines, has announced the initiation of a confirmatory patient study for their biosimilar...

In a rapidly evolving biotech landscape, Alvotech (NASDAQ: ALVO) has steadily positioned itself as a formidable player in the development and manufacturing of biosimilar medicines. Recent announcements from the company...

In a significant development in the biotechnology sector, the European Medicines Agency (EMA) has confirmed its acceptance of Alvotech s marketing application for AVT06, a proposed biosimilar to Eylea (aflibercept). Thi...

Alvotech, a forward-thinking biotech company predominantly focused on the development and manufacturing of biosimilar medicines, is set to report its financial results for the first half of 2024. The announcement will c...